Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 21Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 11Neoplasm Metastasis 11Prostatic Neoplasms 9Melanoma 9Lung Neoplasms 8Glioblastoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Glioma 6Carcinoma, Renal Cell 6Neoplasms 5Colorectal Neoplasms 5Head and Neck Neoplasms 4Uveal Melanoma 3Oligodendroglioma 3Liver Neoplasms 3Gliosarcoma 3Astrocytoma 3Adenocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2

Interventions

Nivolumab 2radium Ra 223 dichloride 1poly ICLC 1fludarabine phosphate 1fludarabine 1darolutamide 1cabozantinib 1bempegaldesleukin 1Radium-223 1Radiosurgery 1Pluvicto 1Cyclophosphamide 1Blood Specimen Collection 1Abiraterone Acetate 1177Lu-EB-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Cancer × Radiosurgery × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡